UBS Maintains Buy on Repligen, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 82.3%

Neg 0% Neu 0% Pos 82.3%

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.

Comments

No comments yet. Be the first!